<DOC>
	<DOCNO>NCT01410890</DOCNO>
	<brief_summary>- The primary objective study characterize pharmacokinetics alglucosidase alfa manufactured 4000 L scale patient confirm diagnosis Pompe disease . - A secondary objective study evaluate explore relationship anti-rhGAA antibody titer pharmacokinetics alglucosidase alfa .</brief_summary>
	<brief_title>Pharmacokinetics Alglucosidase Alfa Patients With Pompe Disease</brief_title>
	<detailed_description>The total study duration per patient 4 9 week consist screening period ( 2 day 4 week ) , treatment visit ( 1 day ) , follow call ( â‰¥30 day ) .</detailed_description>
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<criteria>A patient must meet follow criterion eligible study : The patient and/or patient 's parent/legal guardian willing able provide sign informed consent . The patient confirm GAA enzyme deficiency skin , blood , muscle tissue and/or 2 confirm GAA gene mutation . Infant toddler Pompe disease patient include study condition ( minimal body weight ) trialrelated blood loss ( include loss maneuver ) exceed 3 percent total blood volume period 4 week exceed 1 percent single time . The patient , female childbearing potential , must negative pregnancy test ( urine betahuman chorionic gonadotropin ) screening . Note : All female patient childbearing potential sexually mature male must agree use medically accept method contraception throughout study . For patient previously treat alglucosidase alfa patient receive alglucosidase alfa least 6 month . A patient meet follow criterion exclude study : The patient participate another clinical study use investigational product . The patient , opinion Investigator , unable adhere requirement study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>